Orgonovo and Samsara Sciences
Chief Scientific Officer, Organovo
President, Samsara Sciences
Chapel Hill, NC
Sharon Collins Presnell, PhD, Chief Scientific Officer (Organovo) and President (Samsara Sciences), has more than 17 years of experience in the leadership of product-focused R&D. At the University of North Carolina at Chapel Hill, Dr. Presnell’s research in liver and prostate biology and carcinogenesis produced cell- and tissue-based technologies that were industry-funded or outlicensed for industrial applications. She joined Becton Dickinson (BD) in 2001 and played a key role in the early discovery and development of cell-based tools and reagents for BD’s life sciences portfolio. At BD, she grew and led a large multi-disciplinary team to build and validate screening platforms and products for cell growth, differentiation, and characterization and secured revenue-generating commercial partnerships with pharma partners. Sharon joined Tengion, Inc. in 2007, and as the Senior Vice President of Regenerative Medicine Research, was responsible for leading the discovery and early development of Tengion’s Neo-Kidney Augment™, a clinical-stage cell-based therapy for patients with chronic kidney disease. As the Chief Technology Officer at Organovo, Dr. Presnell led the growth and development of the R&D organization, including evolution of the company’s technology portfolio, and has played an instrumental role in securing funds in support of corporate growth initiatives. In 2015, she led the establishment of Samsara Sciences, Inc., a wholly-owned subsidiary of Organovo, a company focused on the ethical and comprehensive provision of human cellular reagents for discovery and regenerative medicine applications. She currently serves as the President of Samsara Sciences and the Chief Scientific Officer of Organovo. Sharon holds a PhD in pathology from the Medical College of Virginia. Dr. Presnell is a member of the American Society of Investigative Pathology, the American Society of Nephrology, and the International Society of Cell Transplantation, serves on the editorial board of the journal ‘3D Printing and Additive Manufacturing’, and remains active as an NIH reviewer as an industry representative in the biomedical engineering space.